The Paris Commercial Court has granted an extension of receivership proceedings for ACTICOR Biotech, a biopharmaceutical company focused on cardiovascular emergencies. The receivership aims to facilitate the company’s efforts to secure financing, seek partners, and continue the development of its drug, glenzocimab. This extension provides ACTICOR with financial support to operate until January 2025.
Glenzocimab is an innovative antibody fragment that targets the GPVI platelet receptor. It is being evaluated for the treatment of acute ischemic stroke, myocardial infarction, and other thrombotic diseases. In clinical trials, glenzocimab has shown promising results in reducing mortality in intracerebral hemorrhage patients. Phase II trials are currently ongoing to assess its efficacy in reducing myocardial infarction size.
ACTICOR Biotech was founded in 2013 based on the research of INSERM, a French biomedical research institute. The company has been listed on Euronext Growth Paris since November 2021. Its investors include Mediolanum farmaceutici, Karista, and Go Capital.
The company holds three patent families covering the use of glenzocimab in thrombotic diseases. The first family’s patent expires in 2036. Additionally, ACTICOR has the rights to develop a biomarker for stroke patients.
Source link: http://www.businesswire.com/news/home/20241003736426/en/Acticor-Biotech-Extension-of-the-Receivership-Procedure
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
